{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:29:04Z","timestamp":1794432544648,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41434-026-00629-x","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:12:47Z","timestamp":1782803567000},"page":"571-585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Improving the precision of AAV lung gene therapy for SP-B deficiency using computationally derived lung-specific promoters"],"prefix":"10.1038","volume":"33","author":[{"given":"Nicole","family":"Zielinska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin. L.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna A. Y.","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie M.","family":"Goens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena S. B.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison E.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlong","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adithya","family":"Achuthan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arul","family":"Vadivel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Apostol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinghai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Benjamin","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja R.","family":"Srinivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec A. K.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff L.","family":"Caswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis G.","family":"Arroyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren A.","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Thebaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-2406","authenticated-orcid":false,"given":"Sarah K.","family":"Wootton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"key":"629_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3390\/V17020239","volume":"17","author":"L Zwi-Dantsis","year":"2025","unstructured":"Zwi-Dantsis L, Mohamed S, Massaro G, Moeendarbary E. Adeno-associated virus vectors: principles, practices, and prospects in gene therapy. Viruses. 2025;17:239 https:\/\/doi.org\/10.3390\/V17020239.","journal-title":"Viruses"},{"key":"629_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6:1\u201324. https:\/\/doi.org\/10.1038\/s41392-021-00487-6.","journal-title":"Signal Transduct Target Ther"},{"key":"629_CR3","doi-asserted-by":"publisher","unstructured":"Au HKE, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front Med. 2022;8:809118. https:\/\/doi.org\/10.3389\/FMED.2021.809118\/BIBTEX.","DOI":"10.3389\/FMED.2021.809118\/BIBTEX"},{"key":"629_CR4","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1016\/J.YMTHE.2025.04.045","volume":"33","author":"BJ Byrne","year":"2025","unstructured":"Byrne BJ, Flanigan KM, Matesanz SE, Finkel RS, Waldrop MA, D\u2019Ambrosio ES, et al. Current clinical applications of AAV-mediated gene therapy. Mol Ther. 2025;33:2479\u2013516. https:\/\/doi.org\/10.1016\/J.YMTHE.2025.04.045.","journal-title":"Mol Ther"},{"key":"629_CR5","doi-asserted-by":"publisher","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human disease. https:\/\/doi.org\/10.1038\/s41392-024-01780-w.","DOI":"10.1038\/s41392-024-01780-w"},{"key":"629_CR6","doi-asserted-by":"publisher","unstructured":"Muhuri M, Levy DI, Schulz M, McCarty D, Gao G. Durability of transgene expression after rAAV gene therapy. Mol Therapy. 2022:1364\u201380. https:\/\/doi.org\/10.1016\/J.YMTHE.2022.03.004\/ASSET\/92017349-248B-4AA1-8A0C-78F28EC5CB70\/MAIN.ASSETS\/GR5.JPG.","DOI":"10.1016\/J.YMTHE.2022.03.004\/ASSET\/92017349-248B-4AA1-8A0C-78F28EC5CB70\/MAIN.ASSETS\/GR5.JPG"},{"key":"629_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.gt.3302233","volume":"11","author":"TR Flotte","year":"2004","unstructured":"Flotte TR. Gene therapy progress and prospects: recombinant adeno-associated virus (rAAV) vectors. Gene Ther. 2004;11:805\u201310.","journal-title":"Gene Ther"},{"key":"629_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.cytogfr.2024.09.003","volume":"80","author":"D Liu","year":"2024","unstructured":"Liu D, Li T, Liu L, Che X, Li X, Liu C, et al. Adeno-associated virus therapies: Pioneering solutions for human genetic diseases. Cytokine Growth Factor Rev Pergamon. 2024;80:109\u201320.","journal-title":"Cytokine Growth Factor Rev Pergamon"},{"key":"629_CR9","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1089\/HUM.2022.172","volume":"33","author":"G McLachlan","year":"2022","unstructured":"McLachlan G, Alton EWFW, Christopher Boyd A, Clarke NK, Davies JC, Gill DR, et al. Progress in respiratory gene therapy. Hum Gene Ther. 2022;33:893 https:\/\/doi.org\/10.1089\/HUM.2022.172.","journal-title":"Hum Gene Ther"},{"key":"629_CR10","doi-asserted-by":"publisher","first-page":"R88","DOI":"10.1093\/HMG\/DDZ139","volume":"28","author":"Z Yan","year":"2019","unstructured":"Yan Z, McCray PB, Engelhardt JF. Advances in gene therapy for cystic fibrosis lung disease. Hum Mol Genet. 2019;28:R88\u201394. https:\/\/doi.org\/10.1093\/HMG\/DDZ139.","journal-title":"Hum Mol Genet"},{"key":"629_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1089\/HGTB.2015.150","volume":"27","author":"HS Loring","year":"2016","unstructured":"Loring HS, Elmallah MK, Flotte TR. Development of rAAV2-CFTR: history of the first rAAV vector product to be used in humans. Hum Gene Ther Methods 2016;27:49 https:\/\/doi.org\/10.1089\/HGTB.2015.150.","journal-title":"Hum Gene Ther Methods"},{"key":"629_CR12","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1080\/14712598.2017.1347630","volume":"17","author":"WB Guggino","year":"2017","unstructured":"Guggino WB, Cebotaru LAAV. gene therapy for cystic fibrosis: current barriers and recent developments. Expert Opin Biol Ther. 2017;17:1265 https:\/\/doi.org\/10.1080\/14712598.2017.1347630.","journal-title":"Expert Opin Biol Ther"},{"key":"629_CR13","doi-asserted-by":"publisher","first-page":"1476331","DOI":"10.3389\/FPHAR.2024.1476331\/XML\/NLM","volume":"15","author":"LW Plasschaert","year":"2024","unstructured":"Plasschaert LW, MacDonald KD, Moffit JS. Current landscape of cystic fibrosis gene therapy. Front Pharmacol. 2024;15:1476331 https:\/\/doi.org\/10.3389\/FPHAR.2024.1476331\/XML\/NLM.","journal-title":"Front Pharmacol"},{"key":"629_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/JCDD6010008","volume":"6","author":"MG Katz","year":"2019","unstructured":"Katz MG, Fargnoli AS, Gubara SM, Fish K, Weber T, Bridges CR, et al. Targeted gene delivery through the respiratory system: rationale for intratracheal gene transfer. J Cardiovasc Dev Dis. 2019;6:8 https:\/\/doi.org\/10.3390\/JCDD6010008.","journal-title":"J Cardiovasc Dev Dis"},{"key":"629_CR15","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1006\/MTHE.2002.0662\/ASSET\/5CA4A00B-3C4E-4250-9B77-C4DB4E6FE36D\/MAIN.ASSETS\/FX2.JPG","volume":"6","author":"DJ Weiss","year":"2002","unstructured":"Weiss DJ. Delivery of gene transfer vectors to lung: obstacles and the role of adjunct techniques for airway administration. Mol Ther. 2002;6:148\u201352. https:\/\/doi.org\/10.1006\/MTHE.2002.0662\/ASSET\/5CA4A00B-3C4E-4250-9B77-C4DB4E6FE36D\/MAIN.ASSETS\/FX2.JPG.","journal-title":"Mol Ther"},{"key":"629_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/J.1365-2249.2003.02124.X","volume":"132","author":"S Ferrari","year":"2003","unstructured":"Ferrari S, Griesenbach U, Geddes DM, Alton E. Immunological hurdles to lung gene therapy. Clin Exp Immunol. 2003;132:1 https:\/\/doi.org\/10.1046\/J.1365-2249.2003.02124.X.","journal-title":"Clin Exp Immunol"},{"key":"629_CR17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/s41434-022-00332-7","volume":"30","author":"A McCarron","year":"2022","unstructured":"McCarron A, Cmielewski P, Drysdale V, Parsons D, Donnelley M. Effective viral-mediated lung gene therapy: is airway surface preparation necessary? Gene Ther. 2022;30:469\u201377. https:\/\/doi.org\/10.1038\/s41434-022-00332-7.","journal-title":"Gene Ther"},{"key":"629_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/J.OMTM.2018.04.005","volume":"9","author":"LP van Lieshout","year":"2018","unstructured":"van Lieshout LP, Domm JM, Rindler TN, Frost KL, Sorensen DL, Medina SJ, et al. A novel triple-mutant AAV6 capsid induces rapid and potent transgene expression in the muscle and respiratory tract of mice. Mol Ther Methods Clin Dev. 2018;9:323\u20139. https:\/\/doi.org\/10.1016\/J.OMTM.2018.04.005.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"629_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/S00281-024-01003-Y","volume":"45","author":"T Kageyama","year":"2024","unstructured":"Kageyama T, Ito T, Tanaka S, Nakajima H. Physiological and immunological barriers in the lung. Semin Immunopathol. 2024;45:533 https:\/\/doi.org\/10.1007\/S00281-024-01003-Y.","journal-title":"Semin Immunopathol"},{"key":"629_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/IMM.13143","volume":"159","author":"A Ardain","year":"2020","unstructured":"Ardain A, Marakalala MJ, Leslie A. Tissue-resident innate immunity in the lung. Immunology. 2020;159:245\u201356. https:\/\/doi.org\/10.1111\/IMM.13143.","journal-title":"Immunology"},{"key":"629_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/00005237-200401000-00006","volume":"18","author":"MA Wilder","year":"2004","unstructured":"Wilder MA. Surfactant protein B deficiency in infants with respiratory failure. J Perinat Neonatal Nurs. 2004;18:61\u20137. https:\/\/doi.org\/10.1097\/00005237-200401000-00006.","journal-title":"J Perinat Neonatal Nurs"},{"key":"629_CR22","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/S001340050019","volume":"26","author":"M Somaschini","year":"2000","unstructured":"Somaschini M, Wert S, Mangili G, Colombo A, Nogee L. Hereditary surfactant protein B deficiency resulting from a novel mutation. Intens Care Med. 2000;26:97\u2013100. https:\/\/doi.org\/10.1007\/S001340050019.","journal-title":"Intens Care Med"},{"key":"629_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1465-9921-6-32","volume":"6","author":"D Hartl","year":"2005","unstructured":"Hartl D, Griese M. Interstitial lung disease in children \u2013 genetic background and associated phenotypes. Respir Res. 2005;6:1\u201316. https:\/\/doi.org\/10.1186\/1465-9921-6-32.","journal-title":"Respir Res"},{"key":"629_CR24","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/MOP.0000000000000751","volume":"31","author":"LM Nogee","year":"2019","unstructured":"Nogee LM. Genetic causes of surfactant protein abnormalities. Curr Opin Pediatr. 2019;31:330 https:\/\/doi.org\/10.1097\/MOP.0000000000000751.","journal-title":"Curr Opin Pediatr"},{"key":"629_CR25","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1513\/ANNALSATS.201411-507FR\/SUPPL_FILE\/DISCLOSURES.PDF","volume":"12","author":"SH Han","year":"2015","unstructured":"Han SH, Mallampalli RK. The role of surfactant in lung disease and host defense against pulmonary infections. Ann Am Thorac Soc. 2015;12:765\u201374. https:\/\/doi.org\/10.1513\/ANNALSATS.201411-507FR\/SUPPL_FILE\/DISCLOSURES.PDF.","journal-title":"Ann Am Thorac Soc"},{"key":"629_CR26","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.3978\/J.ISSN.2072-1439.2014.04.27","volume":"6","author":"S Kirkby","year":"2014","unstructured":"Kirkby S, Hayes D. Pediatric lung transplantation: indications and outcomes. J Thorac Dis. 2014;6:1024\u201331. https:\/\/doi.org\/10.3978\/J.ISSN.2072-1439.2014.04.27.","journal-title":"J Thorac Dis"},{"key":"629_CR27","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/S0022-3476(97)70348-2","volume":"130","author":"A Hamvas","year":"1997","unstructured":"Hamvas A, Nogee LM, Mallory J, Spray TL, Huddleston CB, August A, et al. Lung transplantation for treatment of infants with surfactant protein B deficiency. J Pediatr. 1997;130:231\u20139. https:\/\/doi.org\/10.1016\/S0022-3476(97)70348-2.","journal-title":"J Pediatr"},{"key":"629_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/J.JPEDS.2017.01.017","volume":"184","author":"WB Eldridge","year":"2017","unstructured":"Eldridge WB, Zhang Q, Faro A, Sweet SC, Eghtesady P, Hamvas A, et al. Outcomes of lung transplantation for infants and children with genetic disorders of surfactant metabolism. J Pediatr. 2017;184:157\u2013164.e2. https:\/\/doi.org\/10.1016\/J.JPEDS.2017.01.017.","journal-title":"J Pediatr"},{"key":"629_CR29","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/J.JPEDS.2006.06.004","volume":"149","author":"LM Palomar","year":"2006","unstructured":"Palomar LM, Nogee LM, Sweet SC, Huddleston CB, Cole FS, Hamvas A. Long-term outcomes after infant lung transplantation for surfactant protein B deficiency related to other causes of respiratory failure. J Pediatr. 2006;149:548\u201353. https:\/\/doi.org\/10.1016\/J.JPEDS.2006.06.004.","journal-title":"J Pediatr"},{"key":"629_CR30","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1172\/JCI15780","volume":"110","author":"A Auricchio","year":"2002","unstructured":"Auricchio A, O\u2019Connor E, Weiner D, Gao G-P, Hildinger M, Wang L, et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins. J Clin Invest. 2002;110:499\u2013504. https:\/\/doi.org\/10.1172\/JCI15780.","journal-title":"J Clin Invest"},{"key":"629_CR31","doi-asserted-by":"publisher","first-page":"785829","DOI":"10.3389\/FGEED.2021.785829\/BIBTEX","volume":"3","author":"AL Cooney","year":"2021","unstructured":"Cooney AL, Wambach JA, Sinn PL, McCray PB. Gene therapy potential for genetic disorders of surfactant dysfunction. Front Genome Ed. 2021;3:785829 https:\/\/doi.org\/10.3389\/FGEED.2021.785829\/BIBTEX.","journal-title":"Front Genome Ed"},{"key":"629_CR32","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1089\/HUM.2022.130","volume":"33","author":"S Sitaraman","year":"2022","unstructured":"Sitaraman S, Alysandratos KD, Wambach JA, Limberis MP. Gene therapeutics for surfactant dysfunction disorders: targeting the alveolar type 2 epithelial cell. Hum Gene Ther. 2022;33:1011 https:\/\/doi.org\/10.1089\/HUM.2022.130.","journal-title":"Hum Gene Ther"},{"key":"629_CR33","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1016\/J.YMTHE.2023.10.002\/ATTACHMENT\/B8C9BE3B-4FE9-46F5-A26F-6285170BED40\/MMC4.MP4","volume":"31","author":"SP Thomas","year":"2023","unstructured":"Thomas SP, Domm JM, van Vloten JP, Xu L, Vadivel A, Yates JGE, et al. A promoterless AAV6.2FF-based lung gene editing platform for the correction of surfactant protein B deficiency. Mol Ther. 2023;31:3457\u201377. https:\/\/doi.org\/10.1016\/J.YMTHE.2023.10.002\/ATTACHMENT\/B8C9BE3B-4FE9-46F5-A26F-6285170BED40\/MMC4.MP4.","journal-title":"Mol Ther"},{"key":"629_CR34","doi-asserted-by":"publisher","first-page":"1271813","DOI":"10.3389\/FGEED.2023.1271813\/BIBTEX","volume":"5","author":"AL Cooney","year":"2023","unstructured":"Cooney AL, Brommel CM, Traore S, Newby GA, Liu DR, McCray PB, et al. Reciprocal mutations of lung-tropic AAV capsids lead to improved transduction properties. Front Genome Ed. 2023;5:1271813 https:\/\/doi.org\/10.3389\/FGEED.2023.1271813\/BIBTEX.","journal-title":"Front Genome Ed"},{"key":"629_CR35","unstructured":"Thomas S. Extending the longevity of AAV-mediated lung gene therapy. [Guelph]: University of Guelph; 2023."},{"key":"629_CR36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1186\/S13287-020-01950-X","volume":"11","author":"H Meyer-Berg","year":"2020","unstructured":"Meyer-Berg H, Zhou Yang L, Pilar de Lucas M, Zambrano A, Hyde SC, Gill DR. Identification of AAV serotypes for lung gene therapy in human embryonic stem cell-derived lung organoids. Stem Cell Res Ther. 2020;11:448 https:\/\/doi.org\/10.1186\/S13287-020-01950-X.","journal-title":"Stem Cell Res Ther"},{"key":"629_CR37","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1038\/S41467-020-17577-8","volume":"11","author":"MH Kang","year":"2020","unstructured":"Kang MH, van Lieshout LP, Xu L, Domm JM, Vadivel A, Renesme L, et al. A lung tropic AAV vector improves survival in a mouse model of surfactant B deficiency. Nat Commun. 2020;11:3929 https:\/\/doi.org\/10.1038\/S41467-020-17577-8.","journal-title":"Nat Commun"},{"key":"629_CR38","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/978-1-60327-248-3_13","volume":"434","author":"C Zheng","year":"2008","unstructured":"Zheng C, Baum BJ. Evaluation of promoters for use in tissue-specific gene delivery. Methods Mol Biol. 2008;434:205 https:\/\/doi.org\/10.1007\/978-1-60327-248-3_13.","journal-title":"Methods Mol Biol"},{"key":"629_CR39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1479-0556-6-13","volume":"6","author":"CA Pacak","year":"2008","unstructured":"Pacak CA, Sakai Y, Thattaliyath BD, Mah CS, Byrne BJ. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther. 2008;6:13 https:\/\/doi.org\/10.1186\/1479-0556-6-13.","journal-title":"Genet Vaccines Ther"},{"key":"629_CR40","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/J.TIBS.2024.03.002","volume":"49","author":"J Guo","year":"2024","unstructured":"Guo J, Lin LF, Oraskovich SV, Rivera de Jes\u00fas JA, Listgarten J, Schaffer DV. Computationally guided AAV engineering for enhanced gene delivery. Trends Biochem Sci. 2024;49:457 https:\/\/doi.org\/10.1016\/J.TIBS.2024.03.002.","journal-title":"Trends Biochem Sci"},{"key":"629_CR41","doi-asserted-by":"publisher","unstructured":"Kabaria SR, Bae Y, Ehmann ME, Beitz AM, Lende-Dorn BA, Peterman EL, et al. Programmable promoter editing for precise control of transgene expression. Nat Biotechnol. 2025. https:\/\/doi.org\/10.1038\/s41587-025-02854-y Online ahead of print.","DOI":"10.1038\/s41587-025-02854-y"},{"key":"629_CR42","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.3390\/CELLS13231963","volume":"13","author":"V Artemyev","year":"2024","unstructured":"Artemyev V, Gubaeva A, Paremskaia AI, Dzhioeva AA, Deviatkin A, Feoktistova SG, et al. Synthetic promoters in gene therapy: design approaches, features and applications. Cells. 2024;13:1963 https:\/\/doi.org\/10.3390\/CELLS13231963.","journal-title":"Cells"},{"key":"629_CR43","doi-asserted-by":"publisher","first-page":"e62727","DOI":"10.3791\/62727","volume":"2021","author":"AD Rghei","year":"2021","unstructured":"Rghei AD, Stevens BAY, Thomas SP, Yates JGE, McLeod BM, Karimi K, et al. Production of adeno-associated virus vectors in cell stacks for preclinical studies in large animal models. JoVE. 2021;2021:e62727 https:\/\/doi.org\/10.3791\/62727.","journal-title":"JoVE"},{"key":"629_CR44","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1152\/AJPLUNG.00011.2003\/ASSET\/IMAGES\/LARGE\/H50931447007.JPEG","volume":"285","author":"KR Melton","year":"2003","unstructured":"Melton KR, Nesslein LL, Ikegami M, Tichelaar JW, Clark JC, Whitsett JA, et al. SP-B deficiency causes respiratory failure in adult mice. Am J Physiol Lung Cell Mol Physiol. 2003;285:543\u20139. https:\/\/doi.org\/10.1152\/AJPLUNG.00011.2003\/ASSET\/IMAGES\/LARGE\/H50931447007.JPEG.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"629_CR45","unstructured":"AAV Edge System | Asimov. https:\/\/www.asimov.com\/aav-edge-system."},{"key":"629_CR46","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/J.YMTHE.2025.01.041","volume":"33","author":"CJ Walkey","year":"2025","unstructured":"Walkey CJ, Snow KJ, Bulcha J, Cox AR, Martinez AE, Ljungberg MC, et al. A comprehensive atlas of AAV tropism in the mouse. Mol Therapy. 2025;33:1282\u201399. https:\/\/doi.org\/10.1016\/J.YMTHE.2025.01.041.","journal-title":"Mol Therapy"},{"key":"629_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1165\/RCMB.2024-0247OC","volume":"73","author":"MH Kang","year":"2025","unstructured":"Kang MH, Thomas SP, Westley C, Blouin T, Xu L, Chan YK, et al. Novel immune response evasion strategy to redose adeno-associated viral vectors and prolong survival in surfactant protein-B-deficient mice. Am J Respir Cell Mol Biol. 2025;73:120\u201334. https:\/\/doi.org\/10.1165\/RCMB.2024-0247OC.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"629_CR48","unstructured":"Powell SK, Rivera-Soto R, Gray SJ. Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy. Discov Med. 2015;19:49. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4505817\/."},{"key":"629_CR49","doi-asserted-by":"publisher","unstructured":"Gon\u00e7alves MAFV. Adeno-associated virus: From defective virus to effective vector. Virol J. 2005;2:1\u201317. https:\/\/doi.org\/10.1186\/1743-422X-2-43\/FIGURES\/6.","DOI":"10.1186\/1743-422X-2-43\/FIGURES\/6"},{"key":"629_CR50","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/J.HLC.2023.06.704\/ASSET\/E33612D4-13FF-4B95-8027-91514650C7A0\/MAIN.ASSETS\/GR3.JPG","volume":"32","author":"N Sasaki","year":"2023","unstructured":"Sasaki N, Kok CY, Westhaus A, Alexander IE, Lisowski L, Kizana E. In search of adeno-associated virus vectors with enhanced cardiac tropism for gene therapy. Heart Lung Circ. 2023;32:816\u201324. https:\/\/doi.org\/10.1016\/J.HLC.2023.06.704\/ASSET\/E33612D4-13FF-4B95-8027-91514650C7A0\/MAIN.ASSETS\/GR3.JPG.","journal-title":"Heart Lung Circ"},{"key":"629_CR51","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/MT.2008.261","volume":"17","author":"MP Limberis","year":"2009","unstructured":"Limberis MP, Vandenberghe LH, Zhang L, Pickles RJ, Wilson JM. Transduction efficiencies of novel AAV vectors in mouse airway epithelium in vivo and human ciliated airway epithelium in vitro. Mol Ther. 2009;17:294\u2013301. https:\/\/doi.org\/10.1038\/MT.2008.261.","journal-title":"Mol Ther"},{"key":"629_CR52","doi-asserted-by":"publisher","first-page":"7827","DOI":"10.1073\/PNAS.0802866105","volume":"105","author":"L Zhong","year":"2008","unstructured":"Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci USA. 2008;105:7827 https:\/\/doi.org\/10.1073\/PNAS.0802866105.","journal-title":"Proc Natl Acad Sci USA"},{"key":"629_CR53","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1016\/J.YMTHE.2023.10.005","volume":"31","author":"A Asokan","year":"2023","unstructured":"Asokan A, Shen S. Redirecting AAV vectors to extrahepatic tissues. Mol Therapy. 2023;31:3371 https:\/\/doi.org\/10.1016\/J.YMTHE.2023.10.005.","journal-title":"Mol Therapy"},{"key":"629_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/GR.4222606","volume":"16","author":"SJ Cooper","year":"2006","unstructured":"Cooper SJ, Trinklein ND, Anton ED, Nguyen L, Myers RM. Comprehensive analysis of transcriptional promoter structure and function in 1% of the human genome. Genome Res. 2006;16:1 https:\/\/doi.org\/10.1101\/GR.4222606.","journal-title":"Genome Res"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00629-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00629-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00629-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:58:35Z","timestamp":1789653515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00629-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00629-x","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"4 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.K.W. and B.T. are scientific and business founders, respectively, of Avamab Pharma Inc., a pre-clinical, pre-revenues stage company dedicated to research and development of AAV gene therapies for the treatment and prevention of infectious diseases. B.Th., and S.K.W. are co-founders of Inspire Biotherapeutics, a pre-clinical, pre-revenue stage company dedicated to research and development of AAV gene therapies for the treatment of monogenic lung diseases. B.Th. and S.K.W. are inventors on a U.S. patent for the AAV6.2FF capsid, which is owned by the University of Guelph. This patent (US20190216949) is licensed to Avamab Pharma Inc. and Inspire Biotherapeutics. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All animal procedures were conducted in compliance with the Canadian Council on Animal Care guidelines and approved by the University of Guelph Animal Care Committee (Animal Utilization Protocol #4664) or the Animal Care and Veterinary Service Committee at the University of Ottawa.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}